Financials Venus Medtech (Hangzhou) Inc.

Equities

2500

CNE100003PJ8

Medical Equipment, Supplies & Distribution

Market Closed - Hong Kong S.E. 03:08:30 2023-11-22 EST 5-day change 1st Jan Change
5.62 HKD -0.71% Intraday chart for Venus Medtech (Hangzhou) Inc. -.--% -.--%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 13,555 28,141 10,561 5,515 2,258 2,258 -
Enterprise Value (EV) 1 11,288 25,422 7,611 4,432 2,183 2,383 2,721
P/E ratio -27.5 x -148 x -28.4 x -5.2 x -3.13 x -7.16 x -11.5 x
Yield - - - - - - -
Capitalization / Revenue 58.1 x 102 x 25.4 x 13.6 x 4.6 x 3.07 x 2.39 x
EV / Revenue 48.4 x 92.1 x 18.3 x 10.9 x 4.44 x 3.24 x 2.88 x
EV / EBITDA -37.7 x -180 x -33.5 x -8 x -4.62 x -9.91 x -25 x
EV / FCF -34,433,168 x -70,410,129 x -13,623,027 x - -2,500,431 x - -
FCF Yield -0% -0% -0% - -0% - -
Price to Book 3.43 x 7.22 x 2.32 x - 0.78 x - -
Nbr of stocks (in thousands) 404,469 422,969 437,897 437,897 437,897 437,897 -
Reference price 2 33.51 66.53 24.12 12.59 5.157 5.157 5.157
Announcement Date 3/27/20 3/31/21 3/31/22 3/31/23 3/28/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 233.3 276 415.9 406.5 491.4 735.3 946
EBITDA 1 -299.1 -140.9 -227 -553.7 -471.9 -240.4 -108.9
EBIT 1 -328 -178.6 -278.6 -666 -596.7 -358.3 -
Operating Margin -140.63% -64.7% -67% -163.86% -121.44% -48.72% -
Earnings before Tax (EBT) 1 -381.5 -185.8 -377.6 -1,156 -752.5 -392.5 -
Net income 1 -380.7 -182 -373.6 -1,058 -720.9 -316.4 -
Net margin -163.21% -65.93% -89.85% -260.22% -146.71% -43.02% -
EPS 2 -1.220 -0.4500 -0.8500 -2.420 -1.650 -0.7200 -0.4500
Free Cash Flow -327.8 -361.1 -558.7 - -872.9 - -
FCF margin -140.53% -130.79% -134.35% - -177.65% - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 - - - - - - -
Announcement Date 3/27/20 3/31/21 3/31/22 3/31/23 3/28/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2
Net sales 1 147.1 102 174 239.3 176.6 210 196.5 255.6 235.8
EBITDA - - - - - - - - -
EBIT 1 - - - -60.08 -218.6 -234.2 -431.8 -329.3 -267.5
Operating Margin - - - -25.11% -123.77% -111.54% -219.77% -128.82% -113.45%
Earnings before Tax (EBT) - - - - - - - - -
Net income - - - - - - - - -
Net margin - - - - - - - - -
EPS 2 - - - -0.2600 -0.5900 -0.4600 -1.960 -0.8000 -0.8500
Dividend per Share - - - - - - - - -
Announcement Date 3/27/20 8/28/20 3/31/21 8/31/21 3/31/22 8/31/22 3/31/23 8/31/23 3/28/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - 125 463
Net Cash position 1 2,267 2,720 2,950 1,083 75.7 - -
Leverage (Debt/EBITDA) - - - - - -0.5206 x -4.251 x
Free Cash Flow -328 -361 -559 - -873 - -
ROE (net income / shareholders' equity) -21.8% -5.07% -8.94% -25.4% -21.6% - -
ROA (Net income/ Total Assets) -16.2% -4.35% -7.93% -19.9% -14.5% - -
Assets 1 2,352 4,180 4,714 5,303 4,966 - -
Book Value Per Share 9.760 9.220 10.40 - 6.620 - -
Cash Flow per Share -0.9800 -0.5800 -1.040 - -1.390 - -
Capex 24.5 124 102 - 263 - -
Capex / Sales 10.52% 44.94% 24.47% - 53.5% - -
Announcement Date 3/27/20 3/31/21 3/31/22 3/31/23 3/28/24 - -
1CNY in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
5.157 CNY
Average target price
8.288 CNY
Spread / Average Target
+60.73%
Consensus
  1. Stock Market
  2. Equities
  3. 2500 Stock
  4. Financials Venus Medtech (Hangzhou) Inc.